CAH
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Cardinal Health, Inc.
- Nom
- Cardinal Health, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Distribution
- Bourse
- NYSE
- Capitalisation
- $57.8B
- Employés
- 61,344
- PDG
- Jason Hollar
- Site web
- https://www.cardinalhealth.com
- Marché
- CORHSICMCKSHPMYSHTDYSIG.AX
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$13,895,718
Avg sell (VWAP, 90d window) $237.34 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-19 | Hollar Jason M. | Sell · S | 6,244 | $237.88 | $1,485,323 | Form 4 |
| 2026-08-19 | Scherer Mary C. | Sell · S | 2,202 | $237.39 | $522,733 | Form 4 |
| 2026-08-18 | Alt Aaron E | Sell · S | 12,972 | $237.26 | $3,077,737 | Form 4 |
| 2026-08-18 | Greene Michelle D. | Sell · S | 686 | $237.25 | $162,754 | Form 4 |
| 2026-08-18 | Hollar Jason M. | Sell · S | 12,470 | $237.25 | $2,958,508 | Form 4 |
| 2026-08-18 | Mason Stephen M | Sell · S | 12,829 | $237.26 | $3,043,809 | Form 4 |
| 2026-08-18 | Mayer Jessica L | Sell · S | 10,864 | $237.31 | $2,578,136 | Form 4 |
| 2026-08-18 | WEITZMAN DEBORAH | Sell · S | 281 | $237.44 | $66,721 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-10-24 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-09-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-05-14 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-05-05 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-03-17 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-01-21 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2024-09-20 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-06-03 | John James | Purchase | $1,001 - $15,000 |
| 2024-05-02 | John James | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-01-12 | Jonathan Jackson | Purchase | $50,001 - $100,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-03 | Kathy E. Manning | Sale (Full) | $1,001 - $15,000 |
| 2022-07-20 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2020-03-18 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-06-20 | Dean Phillips | Sale (Full) | $1,001 - $15,000 |
| 2019-02-04 | Dean Phillips | Purchase | $1,001 - $15,000 |
| 2017-05-08 | Gary James Palmer | Sale (Full) | $1,001 - $15,000 |
| 2017-04-10 | Gary James Palmer | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
CAH presents a moderate opportunity driven by a meaningful congressional trade signal (confidence: 0.72) and a concrete commercial catalyst — the binding LOI extending CVS Health distribution agreements — which aligns…
The first sentence of the analysis written for CAH on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Supports a bullish reading. 6 purchase disclosures year to date
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Pulls against a bullish reading. Current ratio 0.88 · operating margin 1.0%
Market snapshot
Financial ratios
| Metric | Trend | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% | |
| Ebit Margin | 1.0% | 1.0% | 0.6% | 0.4% | -0.4% | |
| Ebitda Margin | 1.4% | 1.4% | 0.9% | 0.7% | 0.0% | |
| Operating Profit Margin | 1.0% | 1.0% | 0.5% | 0.4% | -0.3% | |
| Pretax Profit Margin | 0.9% | 0.9% | 0.5% | 0.3% | -0.4% | |
| Continuous Operations Profit Margin | 0.7% | 0.7% | 0.4% | 0.2% | -0.5% | |
| Net Profit Margin | 0.7% | 0.7% | 0.4% | 0.2% | -0.5% | |
| Bottom Line Profit Margin | 0.7% | 0.7% | 0.4% | 0.2% | -0.5% | |
| Current Ratio | 0.883 | 0.935 | 0.979 | 1.000 | 1.078 | |
| Quick Ratio | 0.489 | 0.502 | 0.559 | 0.522 | 0.566 | |
| Solvency Ratio | 0.044 | 0.042 | 0.032 | 0.022 | -0.006 | |
| Cash Ratio | 0.111 | 0.100 | 0.144 | 0.121 | 0.154 | |
| Price To Earnings Ratio | 32.677 | 25.926 | 28.092 | 75.056 | -15.650 | |
| Price To Earnings Growth Ratio | 2.680 | 0.301 | 0.159 | -0.545 | 0.060 | |
| Forward Price To Earnings Growth Ratio | 2.680 | 0.301 | 0.159 | -0.545 | 0.060 | |
| Price To Earnings Diluted Ratio | 32.858 | 26.047 | 28.336 | 75.056 | -15.650 | |
| Price To Earnings Diluted Growth Ratio | 2.717 | 0.300 | 0.163 | -0.545 | 0.060 | |
| Price To Book Ratio | -19.446 | -14.559 | -7.454 | -8.344 | -20.569 | |
| Price To Sales Ratio | 0.221 | 0.182 | 0.106 | 0.120 | 0.080 | |
| Price To Free Cash Flow Ratio | 12.390 | 21.885 | 7.367 | 10.446 | 5.332 | |
| Price To Operating Cash Flow Ratio | 10.836 | 16.891 | 6.367 | 8.679 | 4.671 | |
| Debt To Assets Ratio | 0.174 | 0.176 | 0.124 | 0.119 | 0.132 | |
| Debt To Equity Ratio | -3.451 | -3.360 | -1.746 | -1.750 | -8.188 | |
| Debt To Capital Ratio | 1.408 | 1.424 | 2.341 | 2.334 | 1.139 | |
| Long Term Debt To Capital Ratio | 1.724 | 1.552 | 3.345 | 4.316 | 1.178 | |
| Financial Leverage Ratio | -19.875 | -19.102 | -14.043 | -14.655 | -61.887 | |
| Working Capital Turnover Ratio | -66.254 | -135.718 | -597.700 | 172.107 | 62.429 | |
| Operating Cash Flow Ratio | 0.118 | 0.062 | 0.106 | 0.084 | 0.102 | |
| Operating Cash Flow Sales Ratio | 0.020 | 0.011 | 0.017 | 0.014 | 0.017 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.875 | 0.772 | 0.864 | 0.831 | 0.876 | |
| Debt Service Coverage Ratio | 1.377 | 2.771 | 2.681 | 1.134 | -0.118 | |
| Interest Coverage Ratio | 7.509 | 10.581 | 24.373 | 8.952 | -4.129 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.817 | 3.357 | 6.828 | 3.188 | 4.578 | |
| Operating Cash Flow Coverage Ratio | 0.520 | 0.257 | 0.671 | 0.549 | 0.538 | |
| Capital Expenditure Coverage Ratio | 7.972 | 4.382 | 7.362 | 5.913 | 8.067 | |
| Dividend Paid And Capex Coverage Ratio | 4.539 | 2.303 | 3.725 | 2.827 | 3.300 | |
| Dividend Payout Ratio | 0.286 | 0.316 | 0.586 | 1.591 | -0.596 | |
| Enterprise Value Multiple | 17.584 | 14.797 | 12.450 | 17.917 | 284.933 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 3.8% | ▲0.2% | ▲0.3% |
| Ebit Margin | 1.0% | ▼-0.1% | ▲0.5% |
| Ebitda Margin | 1.4% | ▼-0.0% | ▲0.5% |
| Operating Profit Margin | 1.0% | ▲0.0% | ▲0.5% |
| Pretax Profit Margin | 0.9% | ▼-0.1% | ▲0.4% |
| Continuous Operations Profit Margin | 0.7% | ▼-0.0% | ▲0.4% |
| Net Profit Margin | 0.7% | ▼-0.0% | ▲0.4% |
| Bottom Line Profit Margin | 0.7% | ▼-0.0% | ▲0.4% |
| Current Ratio | 0.883 | ▼-0.052 | ▼-0.092 |
| Quick Ratio | 0.489 | ▼-0.014 | ▼-0.039 |
| Solvency Ratio | 0.044 | ▲0.002 | ▲0.017 |
| Cash Ratio | 0.111 | ▲0.011 | ▼-0.015 |
| Price To Earnings Ratio | 32.677 | ▲6.751 | ▲3.457 |
| Price To Earnings Growth Ratio | 2.680 | ▲2.380 | ▲2.149 |
| Forward Price To Earnings Growth Ratio | 2.680 | ▲2.380 | ▲2.149 |
| Price To Earnings Diluted Ratio | 32.858 | ▲6.811 | ▲3.528 |
| Price To Earnings Diluted Growth Ratio | 2.717 | ▲2.417 | ▲2.178 |
| Price To Book Ratio | -19.447 | ▼-4.888 | ▼-5.372 |
| Price To Sales Ratio | 0.221 | ▲0.039 | ▲0.079 |
| Price To Free Cash Flow Ratio | 12.390 | ▼-9.495 | ▲0.906 |
| Price To Operating Cash Flow Ratio | 10.836 | ▼-6.055 | ▲1.347 |
| Debt To Assets Ratio | 0.174 | ▼-0.002 | ▲0.029 |
| Debt To Equity Ratio | -3.451 | ▼-0.090 | ▲0.248 |
| Debt To Capital Ratio | 1.408 | ▼-0.016 | ▼-0.321 |
| Long Term Debt To Capital Ratio | 1.724 | ▲0.172 | ▼-0.699 |
| Financial Leverage Ratio | -19.875 | ▼-0.773 | ▲6.038 |
| Working Capital Turnover Ratio | -66.254 | ▲69.465 | ▲46.773 |
| Operating Cash Flow Ratio | 0.118 | ▲0.056 | ▲0.024 |
| Operating Cash Flow Sales Ratio | 0.020 | ▲0.010 | ▲0.005 |
| Free Cash Flow Operating Cash Flow Ratio | 0.875 | ▲0.103 | ▲0.031 |
| Debt Service Coverage Ratio | 1.377 | ▼-1.394 | ▼-0.192 |
| Interest Coverage Ratio | 7.509 | ▼-3.073 | ▼-1.948 |
| Short Term Operating Cash Flow Coverage Ratio | 2.817 | ▼-0.541 | ▼-1.337 |
| Operating Cash Flow Coverage Ratio | 0.520 | ▲0.264 | ▲0.013 |
| Capital Expenditure Coverage Ratio | 7.972 | ▲3.590 | ▲1.233 |
| Dividend Paid And Capex Coverage Ratio | 4.539 | ▲2.236 | ▲1.200 |
| Dividend Payout Ratio | 0.286 | ▼-0.030 | ▼-0.150 |
| Enterprise Value Multiple | 17.584 | ▲2.787 | ▼-51.953 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $56.06B | $40.49B | $23.95B | $24.68B | $14.58B | |
| Enterprise value | $61.16B | $45.96B | $24.43B | $25.78B | $15.67B | |
| EV / Sales | 0.24x | 0.21x | 0.11x | 0.13x | 0.09x | |
| EV / Op. cash flow | 11.82x | 19.17x | 6.49x | 9.07x | 5.02x | |
| EV / Free cash flow | 13.52x | 24.84x | 7.51x | 10.91x | 5.73x | |
| EV / EBITDA | 17.58x | 14.80x | 12.45x | 17.92x | 284.93x | |
| Net debt / EBITDA | 1.46x | 1.76x | 0.24x | 0.76x | 19.78x | |
| Current ratio | 0.88x | 0.94x | 0.98x | 1.00x | 1.08x | |
| Income quality | 3.04x | 1.53x | 4.41x | 8.59x | -3.35x | |
| Graham net-net | -$153 | -$139 | -$109 | -$99 | -$86 | |
| Tax burden | 78.8% | 74.3% | 70.9% | 49.8% | 119.6% | |
| Interest burden | 86.2% | 90.7% | 95.9% | 88.8% | 123.1% | |
| Working capital | -$5.15B | -$2.52B | -$756.0M | -$3.0M | $2.38B | |
| Invested capital | $12.50B | $12.51B | $8.22B | $8.54B | $12.38B | |
| Return on assets | 3.0% | 2.9% | 1.9% | 0.8% | -2.1% | |
| Operating ROA | 4.7% | 4.6% | 2.8% | 1.7% | -1.4% | |
| Return on tangible assets | 3.9% | 3.8% | 2.2% | 0.9% | -2.6% | |
| Return on equity | -59.5% | -56.1% | -26.5% | -11.2% | 132.3% | |
| Return on invested capital | 13.2% | 11.4% | 8.8% | 3.6% | -4.3% | |
| Return on capital employed | 19.5% | 16.0% | 13.1% | 7.8% | -4.6% | |
| Earnings yield | 3.1% | 3.9% | 3.6% | 1.3% | -6.4% | |
| Free cash flow yield | 8.1% | 4.6% | 13.6% | 9.6% | 18.8% | |
| Capex / Op. cash flow | 12.5% | 22.8% | 13.6% | 16.9% | 12.4% | |
| Capex / Depreciation | 67.9% | 69.2% | 72.0% | 69.5% | 53.5% | |
| Capex / Sales | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | |
| SG&A / Sales | 2.4% | 2.4% | 2.2% | 2.3% | 2.5% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | |
| Intangibles / Total assets | 23.8% | 22.9% | 14.3% | 14.0% | 17.4% | |
| Days sales outstanding | 20d | 22d | 19d | 20d | 21d | |
| Days payables outstanding | 57d | 59d | 53d | 55d | 57d | |
| Operating cycle | 46d | 50d | 44d | 49d | 54d | |
| Cash conversion cycle | -11d | -9d | -9d | -6d | -3d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 Cardinal Health (CAH) Outperforms Broader Market: What You Need to Know Cardinal Health (CAH) closed the most recent trading day at $233.12, moving +2.11% from the previous trading session.
- 2026-10-05 Cardinal Health, Inc. $CAH Position Decreased by Park National Corp OH Park National Corp OH trimmed its position in shares of Cardinal Health, Inc. (NYSE: CAH) by 8.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 52,115 shares of the company''s stock after selling 4,578 shares during the
- 2026-10-05 MassMutual Private Wealth & Trust FSB Buys 106,709 Shares of Cardinal Health, Inc. $CAH MassMutual Private Wealth and Trust FSB increased its stake in Cardinal Health, Inc. (NYSE: CAH) by 6,447.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 108,364 shares of the company''s stock after purchasing an additional 106,709 shares during
- 2026-10-01 5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.
- 2026-10-01 Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health DUBLIN, Ohio, Oct. 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health through June 30, 2032, reflecting the continuation of Cardinal Health''s current scope of distribution services. "We value our long-standing partnership with CVS Health and look forward to continuing to bring our best-in-class capabilities together to serve their customers," stated Jason Hollar, CEO of Cardinal Health.
- 2026-10-01 Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5 DUBLIN, Ohio, Oct. 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2027 on November 5, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.
- 2026-09-30 Cardinal Health: I''m Still Buying After Checking The Numbers Cardinal Health remains a Buy, driven by robust FY2026 results, strong cash flow, and credible FY2027 guidance. CAH delivered 14% revenue growth, 20% gross margin expansion, and doubled free cash flow, despite ongoing thin margins and higher current liabilities. FY2027 guidance targets 13-15% non-GAAP EPS growth, with profit improvement expected from both Pharmaceutical and Specialty Solutions and higher-margin ''Other'' segments.
- 2026-09-28 At-Home Healthcare Is Growing Fast: Can CAH Ride the Trend? At-Home Solutions is powering CAH???s growth strategy as investments, acquisitions and technology help it scale in home-based healthcare.
- 2026-09-25 Cardinal Health (CAH) Stock Slides as Market Rises: Facts to Know Before You Trade Cardinal Health (CAH) closed at $220.22 in the latest trading session, marking a -1.08% move from the prior day.
- 2026-09-24 Cardinal Health vs. McKesson: Which Healthcare Stock Is Better? CAH''s specialty-led growth, stronger EPS outlook and improving estimate momentum set up a compelling case against MCK.